Psyence Biomedical Ltd. Common Shares (NASDAQ: PBM) — Healthcare · Share Price, Chart & Market Data
About: Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Sector: Healthcare
Industry: Biotechnology
Latest price: $7.91 (-12.40%)
PBMPsyence Biomedical Ltd. Common Shares
Loading watchlist status…
Trade PBM now
Psyence Biomedical Ltd. Common Shares share price
PBM price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 9:32 am GMT+0
PBM price performance
-16.649%
5D
208.984%
1M
58.398%
YTD
-70.319%
1Y
PBM price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
NASDAQ rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 9:32 am GMT+0
PBM Market Signals